<DOC>
	<DOCNO>NCT01282268</DOCNO>
	<brief_summary>To explore efficacy , safety tolerability STX209 ( arbaclofen ) administer treatment social withdrawal adolescent adult fragile X syndrome ( FXS )</brief_summary>
	<brief_title>Efficacy Safety Study STX209 ( Arbaclofen ) Social Withdrawal Adolescents Adults With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Molecular documentation full FMR1 mutation Current pharmacological treatment regimen stable least 4 week prior Screening . Subjects history seizure disorder must currently receive treatment antiepileptic must seizure free 6 month , must seizure free 3 year currently receive antiepileptic . If subject already receive stable nonpharmacologic educational , behavioral , and/or dietary intervention , participation program must continuous 2 month prior Screening Subjects condition , include alcohol drug abuse , might interfere conduct study , confound interpretation study result , endanger wellbeing . Subjects plan initiate change pharmacologic nonpharmacologic intervention course study . Subjects take another investigational drug within last 30 day . Subjects able take oral medication .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>fragile X syndrome</keyword>
	<keyword>autism spectrum disorder</keyword>
</DOC>